Amgen (NASDAQ:AMGN) Vs. GILD, REGN, VRTX, BIIB, SGEN, ALNY, EXAS, RGEN, INCY, and BMRN
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.
Amgen vs.
Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Amgen has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Regeneron Pharmaceuticals has a net margin of 50.11% compared to Amgen's net margin of 22.55%. Amgen's return on equity of 99.85% beat Regeneron Pharmaceuticals' return on equity.
Amgen received 53 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 74.55% of users gave Amgen an outperform vote while only 68.36% of users gave Regeneron Pharmaceuticals an outperform vote.
74.7% of Amgen shares are owned by institutional investors. Comparatively, 82.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Amgen presently has a consensus price target of $244.00, suggesting a potential upside of 20.12%. Regeneron Pharmaceuticals has a consensus price target of $698.50, suggesting a potential upside of 28.52%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.
Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amgen had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 34 mentions for Amgen and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.32 beat Amgen's score of 0.06 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.
Summary
Regeneron Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip ChartAmgen (NASDAQ:AMGN) vs. Its Competitors
Amgen Competitors List
